Compare Stocks: YDES, NTLA, NUVB, and SEPN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NTLA Intellia Therapeutics	$11.61 -2.5%	$12.27	$7.95 ▼ $28.25	$1.63B	1.8	5.18 million shs	2.90 million shs
NUVB Nuvation Bio	$4.73 +0.1%	$6.13	$3.36 ▼ $9.75	$1.66B	1.61	5.52 million shs	1.79 million shs
SEPN Septerna	$36.44 +0.1%	$39.44	$17.55 ▼ $51.10	$1.70B	2.29	364,887 shs	110,777 shs
YDES YD Bio	$6.37 +4.3%	$4.42	$1.70 ▼ $22.00	$450.51M	-1.55	146,328 shs	14,944 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NTLA Intellia Therapeutics	-5.33%	-3.72%	+1.45%	-8.67%	-49.87%
NUVB Nuvation Bio	-3.51%	-2.86%	-22.60%	-19.78%	+28.22%
SEPN Septerna	-3.04%	+2.10%	-5.43%	+6.90%	+51.18%
YDES YD Bio	-3.63%	-0.81%	+52.50%	+168.72%	+609,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NTLA Intellia Therapeutics	$11.61 -2.5%	$12.27	$7.95 ▼ $28.25	$1.63B	1.8	5.18 million shs	2.90 million shs
NUVB Nuvation Bio	$4.73 +0.1%	$6.13	$3.36 ▼ $9.75	$1.66B	1.61	5.52 million shs	1.79 million shs
SEPN Septerna	$36.44 +0.1%	$39.44	$17.55 ▼ $51.10	$1.70B	2.29	364,887 shs	110,777 shs
YDES YD Bio	$6.37 +4.3%	$4.42	$1.70 ▼ $22.00	$450.51M	-1.55	146,328 shs	14,944 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NTLA Intellia Therapeutics	-5.33%	-3.72%	+1.45%	-8.67%	-49.87%
NUVB Nuvation Bio	-3.51%	-2.86%	-22.60%	-19.78%	+28.22%
SEPN Septerna	-3.04%	+2.10%	-5.43%	+6.90%	+51.18%
YDES YD Bio	-3.63%	-0.81%	+52.50%	+168.72%	+609,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NTLA Intellia Therapeutics	2.26	Hold	$20.72	78.46% Upside
NUVB Nuvation Bio	2.67	Moderate Buy	$13.22	179.84% Upside
SEPN Septerna	2.82	Moderate Buy	$52.44	43.91% Upside
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest YDES, NTLA, NUVB, and SEPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight ➝ Underweight	$8.00
10/6/2026	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Underweight	$8.00
9/30/2026	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Outperform ➝ Buy	$12.00
9/16/2026	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/16/2026	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$10.00
9/16/2026	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$11.00
9/9/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$30.00
9/9/2026	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$12.00 ➝ $13.00
9/9/2026	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$25.00
8/25/2026	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
8/25/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$30.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NTLA Intellia Therapeutics	$67.67M	24.04	N/A	N/A	$5.80 per share	2.00
NUVB Nuvation Bio	$62.90M	26.38	N/A	N/A	$0.88 per share	5.37
SEPN Septerna	$45.95M	37.02	N/A	N/A	$8.53 per share	4.27
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.44	N/A	N/A	N/A	-88.18%	-46.59%	-22.01%	11/2/2026 (Estimated)
SEPN Septerna	-$48.88M	-$0.54	N/A	N/A	N/A	-24.51%	-9.57%	-6.28%	11/9/2026 (Estimated)
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest YDES, NTLA, NUVB, and SEPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	SEPN Septerna	-$0.4150	N/A	N/A	N/A	$20.78 million	N/A
11/5/2026	Q3 2026	NTLA Intellia Therapeutics	-$0.7982	N/A	N/A	N/A	$9.74 million	N/A
11/2/2026	Q3 2026	NUVB Nuvation Bio	-$0.1221	N/A	N/A	N/A	$34.81 million	N/A
9/1/2026	Q2 2026	YDES YD Bio	N/A	$0.05	N/A	$0.0450	N/A	$0.42 million
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	-$0.29	+$0.1360	-$0.29	$19.22 million	$26.75 million
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	-$0.15	-$0.0083	-$0.18	$27.03 million	$31.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NTLA Intellia Therapeutics	N/A	6.65	6.65
NUVB Nuvation Bio	0.96	8.37	8.14
SEPN Septerna	N/A	4.99	4.99
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NTLA Intellia Therapeutics	88.77%
NUVB Nuvation Bio	61.67%
SEPN Septerna	N/A
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
NTLA Intellia Therapeutics	3.50%
NUVB Nuvation Bio	30.11%
SEPN Septerna	5.80%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NTLA Intellia Therapeutics	377	140.13 million	135.22 million	Optionable
NUVB Nuvation Bio	305	351.12 million	245.40 million	Optionable
SEPN Septerna	130	46.68 million	43.97 million	N/A
YDES YD Bio	15	70.79 million	N/A	N/A

YDES, NTLA, NUVB, and SEPN Headlines

Recent News About These Companies

YD Bio Limited (NASDAQ:YDES) Shares Shorted: Short Interest Up 312.8% in September

October 11 at 12:42 PM | americanbankingnews.com

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

October 6, 2026 | globenewswire.com

Cours YD Bio Limited

September 24, 2026 | zonebourse.comZ

YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock

September 11, 2026 | insidertrades.com

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%

September 1, 2026 | finet.hkF

YD Bio Ltd (YDES)

September 1, 2026 | finance.yahoo.com

YD Bio Files First-Half 2026 Results, Reports Improved Equity Position

September 1, 2026 | tipranks.com

YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million

August 31, 2026 | quiverquant.comQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

August 31, 2026 | globenewswire.com

YDES - YD Bio Limited

August 26, 2026 | seekingalpha.com

Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan

August 26, 2026 | zonebourse.comZ

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

August 25, 2026 | globenewswire.com

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES, NTLA, NUVB, and SEPN Company Descriptions

Intellia Therapeutics NASDAQ:NTLA

$11.61 -0.30 (-2.53%)

As of 01:45 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Nuvation Bio NYSE:NUVB

$4.72 +0.01 (+0.11%)

As of 01:45 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Septerna NASDAQ:SEPN

$36.44 +0.02 (+0.06%)

As of 01:45 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

YD Bio NASDAQ:YDES

$6.36 +0.27 (+4.34%)

As of 01:44 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YDES, NTLA, NUVB, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YDES, NTLA, NUVB, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YDES, NTLA, NUVB, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES, NTLA, NUVB, and SEPN Company Descriptions

Intellia Therapeutics NASDAQ:NTLA

Nuvation Bio NYSE:NUVB

Septerna NASDAQ:SEPN

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YDES, NTLA, NUVB, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YDES, NTLA, NUVB, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YDES, NTLA, NUVB, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES, NTLA, NUVB, and SEPN Company Descriptions

Intellia Therapeutics NASDAQ:NTLA

Nuvation Bio NYSE:NUVB

Septerna NASDAQ:SEPN

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools